RECRUITINGPhase 1 / Phase 2INTERVENTIONAL
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Clinical Pharmacogenetic Study of the Efficacy and Safety of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
About This Trial
The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age of all studied subjects ≥ 18 years old
- All patients with hepatocellular carcinoma will be included in group I.
- Patients not treated with systemic TKIs
Who Should NOT Join This Trial:
- Patients presented with liver tumors other than HCC.
- Patients with Child-Pugh grade C for liver function.
- Patients with other malignancies.
- Patients with chronic inflammatory disorders.
- Patients with severe organ dysfunction such as heart, lung, and kidney.
- Patients who cannot tolerate or are allergic to sorafenib.
- Patients with severe coagulation dysfunction were uncorrectable.
- Age less than 18 years old.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age of all studied subjects ≥ 18 years old
* All patients with hepatocellular carcinoma will be included in group I.
* Patients not treated with systemic TKIs
Exclusion Criteria:
* Patients presented with liver tumors other than HCC.
* Patients with Child-Pugh grade C for liver function.
* Patients with other malignancies.
* Patients with chronic inflammatory disorders.
* Patients with severe organ dysfunction such as heart, lung, and kidney.
* Patients who cannot tolerate or are allergic to sorafenib.
* Patients with severe coagulation dysfunction were uncorrectable.
* Age less than 18 years old.
Treatments Being Tested
DRUG
Sorafenib
Sorafenib Tablets (200 -400 mg) twice daily
Locations (1)
NLI
Shibīn al Kawm, Menoufia, Egypt